Ligand Pharmaceuticals Reports the Acquisition of APEIRON Biologics for $100M

Share this
Ligand Pharmaceuticals


Ligand Pharmaceuticals Reports the Acquisition of APEIRON Biologics for $100M


  • Ligand has agreed to acquire APEIRON, along with its royalty rights to Qarziba for high-risk neuroblastoma. APEIRON gets an undisclosed royalty on Qarziba sales outside mainland China from Recordati & within mainland China from BeiGene
  • The company will acquire APEIRON for $100M in cash with APEIRON shareholders receiving additional consideration for future commercial & regulatory milestones plus ~$28M if Qarziba royalties exceed specific target by either 2030 or 2034
  • Ligand will also invest ~$4M in invIOs Holding (spin-off of APEIRON) to fund the development of early-stage immuno-oncology candidates, for which APEIRON will get royalties & milestones. The transaction is anticipated to conclude in Jul 2024

Ref: Ligand | Image: Ligand

Related News:- Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions